Press & Media

Cloudtag’s Proprietary Technology Driven Impact Business Platform

The primary focus of this new platform is a B2B SaaS business model with the primary objective of reducing the likelihood of an overweight or clinically obese person being diagnosed with Type 2 diabetes, whilst enabling B2B medical & pharmaceutical clients to address pre-surgery reimbursement approval.

Update 13-1-20

Following an extremely busy few months, Cloudtag Inc. will be issuing a commercial & technology update in the very near future.

Publication of a single arm medical research concerning Cloudtag’s proprietary technology

Amit Ben-Haim CEO of Cloudtag Inc is very pleased to announce the publication of a single arm medical research concerning Cloudtag’s proprietary technology showing weight loss along with body mass index reduction over the period of the trail at various end points.